BCM
ARRY

Bayesian Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Bayesian Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,900
Closed -$290K – 755
2019
Q1 		$290K Buy
+11,900
New +$248K 0.06% 394
2018
Q3 		– Sell
-23,100
Closed -$388K – 874
2018
Q2 		$388K Buy
23,100
+9,900
+75% +$157K 0.09% 330
2018
Q1 		$215K Buy
+13,200
New +$211K 0.05% 484
2017
Q4 		– Sell
-14,100
Closed -$173K – 800
2017
Q3 		$173K Sell
14,100
-20,100
-59% -$187K 0.04% 436
2017
Q2 		$286K Sell
34,200
-15,200
-31% -$124K 0.11% 301
2017
Q1 		$442K Buy
+49,400
New +$526K 0.21% 188

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bayesian Capital Management's ARRY Position: Q2 2019 in Review

Bayesian Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 11,900 shares — an estimated $290K sold.

Bayesian Capital Management first reported a position in ARRY in Q1 2017 and held it in 6 quarters. The position peaked at $442K in Q1 2017. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Bayesian Capital Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Bayesian Capital Management sold 11,900 Array Biopharma Inc shares in Q2 2019, an estimated $290K.
  • Bayesian Capital Management first reported a position in Array Biopharma Inc in Q1 2017 and held it in 6 quarters.
  • Bayesian Capital Management's Array Biopharma Inc position peaked at $442K in Q1 2017.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Bayesian Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.